Scilex Holding (SCLX) Non Operating Interest Expenses (2021 - 2026)
Scilex Holding (SCLX) posted Non Operating Interest Expenses of $6.1 million for Q2 2026, up 61.52% on a QoQ basis from $3.8 million in Q1 2026, and up 127.59% year-over-year from $2.7 million in Q2 2025.
Analysis
Scilex Holding (SCLX) Non Operating Interest Expenses (2021 - 2026) Analysis & Trends
Scilex Holding has reported Non Operating Interest Expenses for 6 years, with the latest figure at $6.1 million in Q2 2026.
- On a quarterly basis, Non Operating Interest Expenses rose 127.59% year-over-year to $6.1 million in Q2 2026; TTM through Jun 2026 was $16.2 million, a 168.58% increase from a year earlier, with the FY2025 full-year figure at $11.5 million, up 483.75% from the prior year.
- Non Operating Interest Expenses was $6.1 million for Q2 2026 at Scilex Holding, up from $3.8 million in the prior quarter.
- The five-year high for Non Operating Interest Expenses was $6.1 million in Q2 2026, with the low at $7466.0 in Q1 2022.
- Average Non Operating Interest Expenses over 5 years is $2.0 million, with a median of $1.4 million recorded in 2022.
- The sharpest annual moves came in 2023 and 2024: Non Operating Interest Expenses surged 70513.45% in 2023, then tumbled 89.93% in 2024.
- Over 5 years, Non Operating Interest Expenses stood at $1.0 million in 2022, then tumbled by 45.34% to $551000.0 in 2023, then plunged by 48.28% to $285000.0 in 2024, then jumped by 1127.37% to $3.5 million in 2025, then surged by 74.5% to $6.1 million in 2026.
- The last three Non Operating Interest Expenses figures came in at $6.1 million (Q2 2026), $3.8 million (Q1 2026), and $3.5 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | - |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -462.00 Mn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -333.60 Mn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 23.78 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 582,000.00 |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 2.90 Mn |
| 10 | Scilex Holding | 35.91 Mn | -76.88 Mn | 3.97 Mn | 6.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.10 Mn |
| Mar 31, 2026 | 3.78 Mn |
| Dec 31, 2025 | 3.50 Mn |
| Sep 30, 2025 | 2.80 Mn |
| Jun 30, 2025 | 2.68 Mn |
| Mar 31, 2025 | 2.48 Mn |
| Dec 31, 2024 | 285,000.00 |
| Sep 30, 2024 | 576,000.00 |
| Jun 30, 2024 | 571,000.00 |
| Mar 31, 2024 | 531,000.00 |
| Dec 31, 2023 | 551,000.00 |
| Sep 30, 2023 | 513,000.00 |
| Jun 30, 2023 | 3.84 Mn |
| Mar 31, 2023 | 5.27 Mn |
| Dec 31, 2022 | 1.01 Mn |
| Sep 30, 2022 | 1.86 Mn |
| Jun 30, 2022 | 8,280.00 |
| Mar 31, 2022 | 7,466.00 |
| Dec 31, 2021 | 50,000.00 |